Clinical Trial Update: Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors [Phase 1]

View source ↗

Summary

Termination of a Phase 1 safety/tolerance study of PPI-2458 in subjects with Non-Hodgkin lymphoma and solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• PPI-2458

Snippet

Sponsor: PRAECIS Pharmaceuticals Inc. | Conditions: Non-Hodgkin's Lymphoma,, Solid Tumors | Phase 1 | Status: TERMINATED